On February 2, 2022, H. Jeffrey Wilkins resigned as Chief Medical Officer of Avalo Therapeutics, Inc., to be effective upon a date to be agreed upon. Dr. Wilkins will assist in an orderly transition of his duties through the effective date of his resignation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.45 USD | -2.01% | -12.60% | +25.82% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.82% | 11.84M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+37.66% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer